Armata Pharmaceuticals Inc (ARMP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Armata Pharmaceuticals Inc (ARMP) has a cash flow conversion efficiency ratio of 0.045x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.30 Million) by net assets ($-95.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Armata Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1993–2024)
This chart illustrates how Armata Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Armata Pharmaceuticals Inc total liabilities for a breakdown of total debt and financial obligations.
Armata Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Armata Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GAEC Educacao SA
SA:ANIM3
|
0.141x |
|
Kordsa Global Endustriyel Iplik ve Kord Bezi Sanayi ve Ticaret AS
IS:KORDS
|
0.077x |
|
Brooge Holdings Ltd
NASDAQ:BROG
|
0.273x |
|
Jiin Yeeh Ding Enterprise Co Ltd
TWO:8390
|
0.035x |
|
Beijing Bohui Science & Technology Co Ltd
SHG:688004
|
-0.017x |
|
Western New England Bancorp Inc
NASDAQ:WNEB
|
0.023x |
|
Link Net Tbk
JK:LINK
|
0.115x |
|
Jash Engineering Limited
NSE:JASH
|
0.055x |
Annual Cash Flow Conversion Efficiency for Armata Pharmaceuticals Inc (1993–2024)
The table below shows the annual cash flow conversion efficiency of Armata Pharmaceuticals Inc from 1993 to 2024. For the full company profile with market capitalisation and key ratios, see ARMP market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-48.02 Million | $-37.55 Million | 0.782x | -47.12% |
| 2023-12-31 | $-32.06 Million | $-47.42 Million | 1.479x | +264.28% |
| 2022-12-31 | $36.08 Million | $-32.48 Million | -0.900x | +3.02% |
| 2021-12-31 | $25.40 Million | $-23.57 Million | -0.928x | +4.19% |
| 2020-12-31 | $18.86 Million | $-18.27 Million | -0.969x | +9.26% |
| 2019-12-31 | $14.59 Million | $-15.58 Million | -1.068x | +3.56% |
| 2018-12-31 | $8.47 Million | $-9.38 Million | -1.107x | +6.88% |
| 2017-12-31 | $7.73 Million | $-9.19 Million | -1.189x | -9.17% |
| 2016-12-31 | $9.72 Million | $-10.59 Million | -1.089x | -41.56% |
| 2015-12-31 | $12.71 Million | $-9.78 Million | -0.769x | +78.97% |
| 2014-12-31 | $3.44 Million | $-12.57 Million | -3.658x | -798.42% |
| 2013-12-31 | $-14.22 Million | $-7.45 Million | 0.524x | +258.34% |
| 2012-12-31 | $12.94 Million | $-4.28 Million | -0.331x | +49.36% |
| 2011-12-31 | $7.15 Million | $-4.67 Million | -0.653x | -123.91% |
| 2008-12-31 | $-3.77 Million | $-10.30 Million | 2.732x | +419.60% |
| 2007-12-31 | $16.24 Million | $-13.88 Million | -0.855x | +60.57% |
| 2006-12-31 | $5.37 Million | $-11.64 Million | -2.168x | -304.37% |
| 2005-12-31 | $30.57 Million | $-16.39 Million | -0.536x | -71.88% |
| 2004-12-31 | $49.76 Million | $-15.52 Million | -0.312x | +4.92% |
| 2003-12-31 | $34.23 Million | $-11.23 Million | -0.328x | +89.15% |
| 2002-12-31 | $6.65 Million | $-20.10 Million | -3.024x | -380.36% |
| 2001-12-31 | $37.40 Million | $-23.54 Million | -0.629x | -6493.84% |
| 2000-12-31 | $63.43 Million | $-605.54K | -0.010x | +99.37% |
| 1999-12-31 | $7.00 Million | $-10.60 Million | -1.514x | -213.30% |
| 1998-12-31 | $12.00 Million | $-5.80 Million | -0.483x | +78.35% |
| 1997-12-31 | $5.60 Million | $-12.50 Million | -2.232x | -318.53% |
| 1996-12-31 | $19.50 Million | $-10.40 Million | -0.533x | +0.86% |
| 1995-12-31 | $15.80 Million | $-8.50 Million | -0.538x | +1.37% |
| 1994-12-31 | $13.20 Million | $-7.20 Million | -0.545x | -26.45% |
| 1993-12-31 | $10.20 Million | $-4.40 Million | -0.431x | -- |
About Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudo… Read more